IndiTreat ® test effectiveness
IndiTreat® – The potential to predict tumor resistance and sensitivity
Until today, there have been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first-line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance*, causing a measurable burden on clinic resources and immeasurable patient suffering.
Over the last decade, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality. IndiTreat serves you and your clinic with functional information on tumor resistance and sensitivity.
* European Journal of Cancer 81 (2017) 191–202
What does this mean to oncologists and their patients?
Please contact 2cureX for more information
January 20, 2022
2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)
January 26, 2022 at 10:55 (CET)
Mangold Insight Investerardag på tema Life Science - Mangold Fondkommission AB
February 24, 2022
Year-End Report 2021